Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Karuna Therapeutics Inc Market Cap
Based on ratings from 12 stock analysts, the Karuna Therapeutics Inc stock price is expected to increase by 2.73% in 12 months. This is calculated by using the average 12-month stock price forecast for Karuna Therapeutics Inc. The lowest target is $291.00 and the highest is $330.00. Please note analyst price targets are not guaranteed and could be missed completely.
KRTX is a stock in Health Care which has been forecasted to be worth $326.75 as an average. On the higher end, the forecast price is $330.00 USD by jeffrey hung from Morgan Stanley and on the lower end KRTX is forecasted to be $291.00 by david hoang from SMBC Nikko.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| graig suvannavejh Mizuho Securities | Hold | $330.0 | downgraded | Jan 26, 2024 |
| ashwani verma UBS | Hold | $330.0 | maintained | Jan 2, 2024 |
| jessica fye J.P. Morgan | Hold | $330.0 | downgraded | Dec 28, 2023 |
| ram selvaraju H.C. Wainwright | Hold | $330.0 | downgraded | Dec 26, 2023 |
| jason mccarthy Maxim Group | Hold | None | downgraded | Dec 26, 2023 |
| brian abrahams RBC Capital | Hold | $330.0 | downgraded | Dec 22, 2023 |
| mohit bansal Wells Fargo | Hold | $330.0 | downgraded | Dec 22, 2023 |
| myles minter William Blair | Hold | None | downgraded | Dec 22, 2023 |
| david amsellem Piper Sandler | Hold | $330.0 | downgraded | Dec 22, 2023 |
| jason butler JMP Securities | Hold | None | downgraded | Dec 22, 2023 |
| yatin suneja Guggenheim | Hold | None | downgraded | Dec 22, 2023 |
| neena bitritto garg Deutsche Bank | Hold | $330.0 | downgraded | Dec 22, 2023 |
| laura chico Wedbush | Hold | $330.0 | downgraded | Dec 22, 2023 |
| marc goodman Leerink Partners | Hold | $330.0 | downgraded | Dec 22, 2023 |
| jeffrey hung Morgan Stanley | Hold | $330.0 | downgraded | Dec 22, 2023 |
| david hoang SMBC Nikko | Buy | $291.0 | rated | Dec 12, 2023 |
| jay olson Oppenheimer | Buy | $280.0 | maintained | Nov 20, 2023 |
| jason gerberry Bank of America Securities | Buy | $260.0 | reiterated | Nov 16, 2023 |
| caroline palomeque Berenberg Bank | Buy | $282.0 | maintained | Aug 4, 2023 |
| charles duncan Cantor Fitzgerald | Hold | $214.0 | reiterated | Aug 3, 2023 |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
When did it IPO
2019
Staff Count
210
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. William Meury
Market Cap
$12.13B
In 2023, KRTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KRTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
HOOD-USD
$14.09
MEDP-USD
$391.64
$45.45
LNT-USD
$48.35
MSTR-USD
$699.56
MORN-USD
$273.91
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
